Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years

摘要: Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of single center study alemtuzumab as induction renal transplantation. Thirty-three transplant recipients received 20mg on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75–125 ng/mL) from 3. They were compared retrospective contemporaneous-controlled manner with 66 kidney transplanted the same period who conventional immunosuppression cyclosporin, azathioprine prednisolone. In group 12% died to 17% control (p = 0.48); likewise graft loss was similar both groups (21% vs. 26%, respectively, p 0.58). Incidence acute rejection also comparable at 5 years (31.5% 33.6%), although pattern different 14% patients experiencing over 1 year post-transplant none group. There no significant difference between terms infection or serious adverse events. While acknowledging limitations relatively small single-center study, suggest that allowed satisfactory long-term patient survival equivalent seen standard triple immunosuppression, while avoiding steroid therapy.